I think the potential of Agenic is to rethink how work gets done overall. It challenges all sorts of

traditional orthodoxies around how organizations execute the work at hand. That's Jason Gersatus,

CEO of Deloitte U.S., talking about the transformational potential of Agenic AI. Join him later to

learn why agents are a game changer for businesses across industries.

Here's your T&B Tech Minute for Thursday, June 11th. I'm Danny Lewis for the Wall Street Journal.

We exclusively report that OpenAI is considering drastically lowering the prices it charges users

as it seeks to win customers from Anthropic. People familiar

with the matter say the move by the chat GPT maker would be in anticipation of similar cuts expected

by its rival. Business executives are beginning to balk at the high prices for AI usage as the two

companies are trying to win over enterprise customers. But drastic price cuts could potentially erode the company's profit

margins, which already lose billions of dollars due to the enormous costs of AI computing

resources. News Corp, owner of the Wall Street Journal, has a content licensing partnership with

OpenAI. Speaking of Anthropic, the Claude Chatbot maker's latest AI model is facing backlash from some users over the broad restrictions on its capabilities.

The company previously said its mythos model was too dangerous to release widely because of fears around cybersecurity and bioweapon development.

Some AI experts accused Anthropic of hiding some limitations to the update, called Claude Fable 5, including quietly

degrading the quality of its responses about developing high-end AIs, while others found that

Fable 5 refused to answer any questions about biology, mathematics, and chemistry. In a statement,

Anthropics said it would make some safeguards visible and is working to reduce unnecessary obstructions.

Plus, in another WSJ exclusive, we report that NVIDIA is partnering with a bridge, an AI

note-taking app maker, to train a model focused on health care. The company said the AI is

designed for clinical conversations and will be used exclusively within a bridge's platform to

improve tasks like clinical decision support and documentation.

...